{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 52/80', '6.11. SCHEDULE OF ACTIVITIES', 'For detailed instructions on the clinical study procedures, please see referred Sections and Section 6.1, \"Timing of Assessments\".', 'EVENT', 'SCREENING', 'TREATMENT PERIOD', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', 'ED', 'FU1', 'FU2', 'Study Day (D) or Week (W)b days (d)', 'W2', 'W4', 'W8', 'W12\u00b0', 'W16', 'W20C', 'W24', 'W28', 'W36', 'D-28 to D-1', 'D1', '2d', '2d', '+4d', '+4d', '+4d', '+4d', '+4d', '7d', '7d', 'Informed consent (Section 6.3)', 'Inclusion/exclusion criteria (Section 6.3)', 'Demographics (Section 6.3)', 'Medical history/concurrent illnesses (Section 6.3)', 'FSH test (Section 6.6.2)', 'Randomization (Section 4.6.1)', 'Phone call', 'Pregnancy test d (Section 6.6.2)', 'Physical examination (Section 6.6.3)', 'Vital signs (Section 6.6.4)', '12-Lead ECGe (Section 6.6.5)', 'Serology (Section 6.6.2)', 'Clinical laboratory tests (Section 6.6.2)', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 53/80', 'EVENT', 'SCREENING', 'TREATMENT PERIOD', 'FOLLOW-UP', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', 'ED', 'FU1', 'FU2', 'Study Day (D) or Week (W) days (d)', 'W2', 'W4', 'W8', 'W12\u00b0', 'W16', 'W20\u00b0', 'W24\u00b9', 'W28', 'W36', 'D-28 to D-1', 'D1', '2d', '2d', '+4d', '+4d', '+4d', '+4d', '+4d', '7d', '7d', 'mRSS (Section 6.5.1)', 'Dispense subject diary', 'Collect subject diary', 'Dispense IMP', 'Review IMP compliance', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 54/80', 'EVENT', 'SCREENING', 'TREATMENT PERIOD', 'FOLLOW-UP', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9', 'ED', 'FU1', 'FU2', 'Study Day (D) or Week (W) days (d)', 'W2', 'W4', 'W8', 'W12\u00b0', 'W16', 'W20\u00b0', 'W24\u00b9', 'W28', 'W36', 'D-28 to D-1', 'D1', '2d', '2d', '+4d', '+4d', '+4d', '+4d', '+4d', '7d', '7d', 'Dose IMP (Section 5.2)', 'q.d. throughout the treatment period', 'AE assessment (Section 6.6.1)', 'Throughout the study', 'Concomitant medication assessment and', 'Throughout the study', 'documentation (Section 4.5.3.2)', 'FU=follow-up, QoL=quality of life.', 'a ED visit if applicable.', 'b Week is defined as 7 days.', 'c This will be a phone call to assess safety (no clinical study center visit).', 'd', 'Serum pregnancy test at screening, urine pregnancy test at all other visits.', 'e Triplicate ECGs will be performed irrespective of IMP intake at Visit 1 (screening), within 30 minutes before IMP intake and between 2 to 3 hours after IMP intake at', 'Visit 2 (baseline) and Visit 3. A single ECG will be performed within 30 minutes before IMP intake at Visits 7 and 9, and irrespective of IMP intake at ED (if applicable) and', 'Follow-up Visit 1.', 'i If Visit 9 (Week 24) cannot be conducted within the time window of +4 days, the visit window can be extended to 28 days (i.e. can be extended or shortened up to 28 days)', 'to enable conduct of thevisiton site. IfVisit 9is conducted afterWeek 24,additional regular phone calls at Week 24 and every 14 days thereafter should be implemented,', \"until an on-site Visit 9 can take place, or until Week 32, to evaluate the subject's safety. In addition, if any of the follow-up visits cannot be performed on-site, a phone call to\", \"evaluate the subject's safety should be performed on the date of the visit. The information to be collected during these phone calls is detailed in\", 'Section', '6.6.', 'j The FU visits need to be scheduled in relation to the last dose of IMP. FU1 should be 28 days 7 days after the last IMP administration, and FU2 should be 84 days 7 days', 'after the last IMP administration.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}